Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat for sickle cell disease
2024-515202-84-00Phase 3Authorised
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Mitapivat with Placebo (2 arms). Primary endpoints: Hemoglobin response and Annualized rate of sickle cell pain crises. Planned start Aug 2024; status: authorised.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-515202-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515202-84-00.